– Totality of data from these ongoing studies suggest clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modification –– Phase 1/2a ADMIRAL Study Data STK-001 (70mg): Patients treated with 2 or 3 ini.
Operator: Greetings and welcome to the Marinus Pharmaceuticals’ First Quarter 2023 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode.
Nina Mago lives in Uganda and runs the Purple Bench Initiative - Uganda. In 2019, she represented the entire continent of Africa at the 33rd International Epilepsy Congress in Bangkok, Thailand, as a Golden Light Award winner. Learn about her remarkable story of speaking up for people living with